BR112018011310A2 - mutante da proteína l1 do papilomavírus humano tipo 58 - Google Patents

mutante da proteína l1 do papilomavírus humano tipo 58

Info

Publication number
BR112018011310A2
BR112018011310A2 BR112018011310-7A BR112018011310A BR112018011310A2 BR 112018011310 A2 BR112018011310 A2 BR 112018011310A2 BR 112018011310 A BR112018011310 A BR 112018011310A BR 112018011310 A2 BR112018011310 A2 BR 112018011310A2
Authority
BR
Brazil
Prior art keywords
protein
hpv
infection
types
particle
Prior art date
Application number
BR112018011310-7A
Other languages
English (en)
Chinese (zh)
Inventor
Li Shaowei
Li Zhihai
Song Shuo
He Maozhou
Gu Ying
Xia Ningshao
Original Assignee
Xiamen Univeristy
Xiamen Innovax Biotech Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen Univeristy, Xiamen Innovax Biotech Co., Ltd. filed Critical Xiamen Univeristy
Publication of BR112018011310A2 publication Critical patent/BR112018011310A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

são fornecidas uma proteína l1 de hpv58 mutada ou uma sua variante, uma sequência que codifica a mesma, um método para a preparação da mesma e uma partícula semelhante a vírus compreendendo a mesma, em que a proteína ou uma sua variante e a partícula semelhante a vírus podem induzir a gerao de anticorpos neutralizantes contra pelo menos dois tipos de hpv e, por conseguinte, pode ser utilizada para prevenir infeco pelos referidos pelo menos dois tipos de hpv e uma doen causada pela referida infeco, tal como cancro do colo do ero e condiloma acuminado. a inveno refere-se ainda utilizao da protea e da partula semelhante a vus no fabrico de uma composio farmactica ou uma vacina para prevenir infeco pelos referidos pelo menos dois tipos de hpv, e uma doen causada pela referida infeco, tal como cancro do colo do ero e condiloma acuminado.
BR112018011310-7A 2015-12-04 2016-12-02 mutante da proteína l1 do papilomavírus humano tipo 58 BR112018011310A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510882847 2015-12-04
CN201510882847.1 2015-12-04
PCT/CN2016/108345 WO2017092710A1 (zh) 2015-12-04 2016-12-02 一种人乳头瘤病毒58型l1蛋白的突变体

Publications (1)

Publication Number Publication Date
BR112018011310A2 true BR112018011310A2 (pt) 2018-11-27

Family

ID=58796310

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011310-7A BR112018011310A2 (pt) 2015-12-04 2016-12-02 mutante da proteína l1 do papilomavírus humano tipo 58

Country Status (7)

Country Link
US (1) US10940194B2 (pt)
EP (1) EP3385273A4 (pt)
JP (1) JP6958818B2 (pt)
KR (1) KR102351259B1 (pt)
CN (1) CN106831961B (pt)
BR (1) BR112018011310A2 (pt)
WO (1) WO2017092710A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109251236B (zh) * 2017-07-14 2021-09-28 厦门大学 一种人乳头瘤病毒35型l1蛋白的突变体
US11464846B2 (en) * 2018-06-04 2022-10-11 Xiamen University Mutant of L1 protein of human papillomavirus type 66
US20220001002A1 (en) * 2018-09-26 2022-01-06 Xiamen University Mutant of l1 protein of human papillomavirus type 51
WO2021013075A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒18型l1蛋白
CN114127100B (zh) * 2019-07-19 2024-04-02 神州细胞工程有限公司 嵌合的人乳头瘤病毒39型l1蛋白
WO2021013076A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒45型l1蛋白
MY197457A (en) * 2019-07-19 2023-06-19 Sinocelltech Ltd Chimeric papillomavirus l1 protein
CN117054647A (zh) * 2023-07-17 2023-11-14 广东省一鼎生物技术有限公司 一种检测HPV IgG抗体试剂盒及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689366B1 (en) * 1998-12-17 2004-02-10 Merck & Co., Inc. Synthetic virus like particles with heterologous epitopes
US6551597B1 (en) 1999-03-18 2003-04-22 President & Fellows Of Harvard College Vaccine compositions for human papillomavirus
ES2381964T3 (es) 2003-03-24 2012-06-04 Merck Sharp & Dohme Corp. Expresión optimizada de L1 de VPH 31 en levadura
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
CN101518647A (zh) 2008-02-29 2009-09-02 江阴艾托金生物技术有限公司 人乳头瘤病毒预防性疫苗、构建方法及应用
ES2653251T3 (es) 2009-04-10 2018-02-06 The Johns Hopkins University Partículas de tipo papilomavirus (VLP) como vacunas de amplio espectro del virus del papiloma humano (VPH)
US20120087937A1 (en) * 2009-06-25 2012-04-12 Brigitte Desiree Alberte Colau Novel compositions
DK2589604T3 (en) 2010-07-02 2017-01-16 Univ Xiamen TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 52
US9382296B2 (en) * 2010-07-16 2016-07-05 Xiamen University Truncated L1 protein of human papillomavirus type 58
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
CN102552897B (zh) * 2012-01-18 2013-10-30 广东华南联合疫苗开发院有限公司 一种宫颈癌预防性vlp疫苗
KR101331097B1 (ko) 2012-05-23 2013-11-19 주식회사 코아로직 필름 영상을 티브이 영상으로 변환하기 위한 방법 및 장치
CN105175538B (zh) * 2012-06-08 2019-01-08 厦门大学 抗hpv l1 蛋白的广谱单克隆抗体或其抗原结合片段及它们的用途
CN103992395B (zh) 2013-02-18 2018-07-27 北京康乐卫士生物技术股份有限公司 重组hpv-58型l1的vlp疫苗及其制备方法
CN104231060B (zh) * 2013-06-05 2018-05-15 厦门大学 人乳头瘤病毒l1l2衣壳蛋白相互作用位点及其应用

Also Published As

Publication number Publication date
EP3385273A4 (en) 2019-08-07
US10940194B2 (en) 2021-03-09
JP6958818B2 (ja) 2021-11-02
EP3385273A1 (en) 2018-10-10
CN106831961B (zh) 2019-11-05
CN106831961A (zh) 2017-06-13
US20200268869A1 (en) 2020-08-27
JP2019504110A (ja) 2019-02-14
KR102351259B1 (ko) 2022-01-14
KR20180100126A (ko) 2018-09-07
WO2017092710A1 (zh) 2017-06-08

Similar Documents

Publication Publication Date Title
BR112018011310A2 (pt) mutante da proteína l1 do papilomavírus humano tipo 58
BR112018011331A2 (pt) mutante de proteìna l1 de papillomavirus humano tipo 11
EP4233898A3 (en) Influenza mrna vaccines
WO2018115527A3 (en) Mers coronavirus vaccine
WO2016198531A3 (en) Hpv vaccines
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
BR112019000598A2 (pt) rna para terapia de câncer
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
BR112013030150A2 (pt) proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112015021974A2 (pt) Composição, e, método de indução de uma resposta imune
IN2014DN03054A (pt)
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
BR112018075420A2 (pt) melhoramento da imunogenicidade de petídeo l2
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
AU2014232363A8 (en) Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
BR112015023738B8 (pt) Vacinas de nucleoproteina influenza

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]